Beam Therapeutics Base Editing Improved GSDIa Fasting
Initial phase 1/2 clinical data show promise for a liver-targeting gene editing treatment in patients with GSDIa.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Should medical research prioritize gene editing to treat the underlying causes of rare genetic diseases?
Beam Therapeutics has reported early clinical trial results for BEAM-301, an experimental base editing treatment for glycogen storage disease Ia (GSDIa). As of June 2026, six patients have received the therapy, which aims to correct the R83C mutation.
Why it matters
GSDIa causes severe glucose-6-phosphatase deficiency, forcing patients to manage life-threatening hypoglycemia through frequent starch intake. This treatment seeks to address the underlying genetic cause of the metabolic impairment.
Patients in the 20 mg cohort saw median fasting hypoglycemia time increase from 2.9 to 4.3 hours by day 36, while the 40 mg cohort achieved a 15-hour controlled fast.
The players
Beam Therapeutics
A biotechnology company headquartered in Cambridge, Massachusetts, focused on developing precision genetic medicines using base editing technology.
The details
BEAM-301 uses lipid nanoparticles — microscopic fat-based spheres used for cellular delivery — to transport base editing reagents to the liver. Once inside, the treatment corrects the R83C genetic mutation, which prevents the production of essential glucose-6-phosphatase. The trial reported five serious adverse events, including three Grade 3 infusion-related reactions, though all transaminase elevations, or signs of liver stress, resolved without medical intervention.
Timeline
June 26, 2026: Data cutoff for the reported clinical study results.
October 27, 2026: Investor webcast regarding the clinical trial data.
October 27-30, 2026: 33rd Annual Congress of the European Society of Gene and Cell Therapy occurs in Hamburg, Germany.
October 28, 2026: Poster presentation of BEAM-301 clinical data.
The Tech Race
This development follows a pattern set by clinical data disclosures at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress. The event serves as a major forum for evaluating the trajectory of in vivo base editing programs against established gene therapy benchmarks.
The treatment remains in the research phase and is not currently available for patients. Future clinical milestones will determine if the therapy can safely reduce the current burden of daily, frequent starch intake for GSDIa patients.
The takeaway
This trial demonstrates that base editing can potentially restore metabolic function in patients with GSDIa. Investors and patients should monitor the updated safety and efficacy data to be presented on October 28, 2026, for evidence of long-term durability.
What happens next
Beam Therapeutics will host an investor webcast on October 27, 2026, followed by a formal poster presentation at the ESGCT congress on October 28, 2026.
Further reading
Learn more about the latest developments in precision medicine at Biotech.
More information
View the clinical trial updates via the Beam Therapeutics investor and events portal.
Live Poll
Should medical research prioritize gene editing to treat the underlying causes of rare genetic diseases?
